Skip to main content
SpringerLink
Log in

Short -term intensive neoadjuvant chemotherapy improving 10-year survival for patients with stage II and operable stage III breast cancer

  • Original Article
  • Published:
Chinese Journal of Clinical Oncology

Abstract

Objective

To evaluate the 10-year curative effects of short-term intensive neoadjuvant chemotherapy for operable breast cancer.

Methods

A total of 510 patients with stagell and operable stagelll breast cancer were divided into group A (preoperative neoadjuvant chemotherapy 251 cases) and group B (postoperative adjuvant chemotherapy 259 cases). The patients in group A received short -term and intensive neoadjuvant chemotherapy for 4 weeks followed by modified radical mastectomy two weeks after the chemotherapy. The postoperative adjuvant chemotherapy began within two weeks after surgery. The same chemotherapeutic regimen was used for both groups.

Results

For stage III in group A the 5-year overall survival rate (OS) and disease-free survival rate (DFS) were 59.2% and 54.9% respectively which were higher than those in group B (28.3% and 20.8% respectively,P<0.05). The 10-year OS and DFS were 78.1% and 73.5% respectively for stage II in group A which were higher than those in group B (68.4% and 60.7%,P< 0.05). The 10-year OS and DFS were 42.3% and 40.4% respectively for stage III in group A which were higher than those in group B (20.4% and 18.4% respectively,P<0.05).

Conclusion

The results showed that intensive neoadjuvant chemotherapy can improve the 10-year survival for patients with stage II and operable stage III breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Quiet CA. Ferguson DJ. Weichselbaum RR. et al. Natural history of node-negative breast cancer: A study of 826 patients with long-term follow-up. J Clin Oncol, 1995;13: 1144.

    PubMed  CAS  Google Scholar 

  2. Zhang B, Cha YE, Zhang Q, et al. Combination therapy of locally advanced breast cancer. Chinese Journal of Clinical Oncology, 1997;24:138.

    Google Scholar 

  3. Fisher B, Anderson S, Wickerham D, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophophamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol, 1997; 15:1858.

    PubMed  CAS  Google Scholar 

  4. Fisher B, Anderson S, DeCillis A, et al. Further evaluation of intensified and increased total dose of cyclophophamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol, 1999;17:3374.

    PubMed  CAS  Google Scholar 

  5. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol, 2003;21:976.

    Article  PubMed  CAS  Google Scholar 

  6. Estevez LG, Cuevas JM, Anton A, et al. Weekly docetaxel as neoadjuvant chemotherapy for stage and breast cancer: efficacy and correlation with biological marker in a phase, multicenter study. Clin Cancer Res, 2003;9:686.

    PubMed  CAS  Google Scholar 

  7. Jackisch C, von Minckwitz G, Eidtmann H, et al. Dose — dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophos-phamide/docetaxel in operable breast cancer: second interim analysis. Clin Breast Cancer, 2002;3:276.

    Article  PubMed  CAS  Google Scholar 

  8. Harris EE, Schultz D, Bertsch H, et al. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys, 2003;55:1200.

    Article  PubMed  Google Scholar 

  9. Cance WG, Carey LA, Calvo BF, et al. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg, 2002; 236:295.

    Article  PubMed  Google Scholar 

  10. Stebbing J J, Gaya A. The evidence-based use of induction chemotherapy in breast cancer. Breast Cancer, 2001; 8:23.

    CAS  Google Scholar 

  11. Buchholz TA, Hunt KK, Whitman GJ, et al. Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer, 2003;98:1150.

    Article  PubMed  Google Scholar 

  12. Mamounas EP. Neoadjuvant chemotherapy for operable breast cancer: is this the future? Clin Breast Cancer,2003; Suppl l:S10.

  13. Pierga JY, Mouret E, Laurence V, et al. Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. the role of clinical response. Eur J Cancer, 2003;39:1089.

    Article  PubMed  Google Scholar 

  14. Onnefoi H, Diebold-Berger S, Therasse P, et al. Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? Ann Oncol, 2003;14:406.

    Article  Google Scholar 

  15. Wang J, Buchholz TA, Middleton LP, et al. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer, 2002;94:3107.

    Article  PubMed  CAS  Google Scholar 

  16. Penault-Llorca F, Cayre A, Bouchet Mishellany F, et al. Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol, 2003;22: 1319.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Breast Cancer, Liaoning Province Tumor Hospital, 110042, Shenyang, China

    Bin Zhang, Yue Cai, Qi Zhang, Ziwei Ying, Shuling Jiang, Hong Xu, Yongxue Zheng & Daqing Jiang

Authors
  1. Bin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yue Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qi Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ziwei Ying
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shuling Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hong Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yongxue Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Daqing Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Zhang, B., Cai, Y., Zhang, Q. et al. Short -term intensive neoadjuvant chemotherapy improving 10-year survival for patients with stage II and operable stage III breast cancer. Chin. J. Clin. Oncol. 1, 42–46 (2004). https://doi.org/10.1007/BF02739856

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02739856

Keywors

Search

Navigation